Center for Scientific Review; Notice of Closed Meetings, 7820 [2016-02974]
Download as PDF
<![CDATA[
7820
Federal Register / Vol. 81, No. 30 / Tuesday, February 16, 2016 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: AIDS and Related
Research Integrated Review Group, AIDS
Discovery and Development of Therapeutics
Study Section.
Date: March 8, 2016.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Shiv A Prasad, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5220,
MSC 7852, Bethesda, MD 20892, 301–443–
5779, prasads@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Infectious
Diseases and Microbiology.
Date: March 8, 2016.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Guangyong Ji, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3211,
MSC 7808, Bethesda, MD 20892, 301–435–
1146, jig@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, AREA
application in Infectious Diseases and
Microbiology.
Date: March 8, 2016.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Liangbiao Zheng, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3202,
MSC 7808, Bethesda, MD 20892, 301–996–
5819, zhengli@csr.nih.gov.
VerDate Sep<11>2014
22:15 Feb 12, 2016
Jkt 238001
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 9, 2016.
Sylvia Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–02974 Filed 2–12–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209
and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing and/or co-development.
SUMMARY:
Invention Development and
Marketing Unit, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, Mail Stop 9702,
Rockville, MD 20850–9702.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Information on licensing and codevelopment research collaborations,
and copies of the U.S. patent
applications listed below may be
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD,
20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
AAV-based Vectors for the
Therapeutic Management of Menkes
Disease and Related Copper Transport
Disorders
Frm 00079
Fmt 4703
The only currently available treatment
for Menkes disease, subcutaneous
copper histidinate injections, is
successful only in patients with ATP7A
gene mutations that do not completely
corrupt ATP7A copper transport
function (estimated 20–25% of affected
patients) and when started at a very
early age (first month of life). The
combination of viral gene therapy with
copper injections provides working
copies of the ATP7A copper transporter
into the brain, together with a source of
the substrate (copper) needed for proper
brain growth and clinical
neurodevelopment.
Codon-optimized nucleic acids
encoding a reduced-size ATP7A protein
and compositions of AAV vectors were
discovered by NICHD researchers along
with methods of administering this
therapy. Human P-type ATPase coppertransporting ATPase 1 (ATP7A)
transports copper from enterocytes
(where it is taken up from dietary
copper) into the blood. ATP7A also
mediates passage of copper across the
blood-cerebrospinal fluid (CSF) barrier
and the blood-brain barrier. In Menkes
disease and occipital horn syndrome
(OHS), copper accumulates in intestinal
cells and less copper is absorbed into
the blood, resulting in restricted copper
supply to other tissues, particularly the
brain. Death in infancy or early
childhood is a common consequence.
Therapeutic delivery of the copper
transport protein via an AAV vector,
combined with subcutaneous copper
histidinate treatment will relieve the
copper deficiency to the brain and
permit normal neurological
development and function.
Potential Commercial Applications
• Treatment of Menkes Disease,
Occipital Horn Syndrome, and of
ATP7A-related distal motor neuropathy
Value Proposition
• Provides working copies of the
ATP7A copper transporter into the
brain, together with a source of the
substrate (copper) needed for proper
brain growth and clinical
neurodevelopment.
Development Stage
Pre-clinical (in vivo validation)
Inventor(s)
Stephen G. Kaler, M.D. (NICHD)
Title of Invention
PO 00000
Description of Technology
Sfmt 4703
Intellectual Property
HHS Reference No. E–062–2015/0
U.S. Provisional Application No. 62/
244,594 filed 21 October 2015
E:\FR\FM\16FEN1.SGM
16FEN1
]]>Agencies
[Federal Register Volume 81, Number 30 (Tuesday, February 16, 2016)]
[Notices]
[Page 7820]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-02974]
[[Page 7820]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: AIDS and Related Research Integrated Review
Group, AIDS Discovery and Development of Therapeutics Study Section.
Date: March 8, 2016.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda,
MD 20814.
Contact Person: Shiv A Prasad, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5220, MSC 7852, Bethesda, MD 20892, 301-443-
5779, prasads@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel, Infectious Diseases and Microbiology.
Date: March 8, 2016.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Guangyong Ji, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3211, MSC 7808, Bethesda, MD 20892, 301-435-
1146, jig@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel, AREA application in Infectious Diseases and Microbiology.
Date: March 8, 2016.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Liangbiao Zheng, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3202, MSC 7808, Bethesda, MD
20892, 301-996-5819, zhengli@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: February 9, 2016.
Sylvia Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-02974 Filed 2-12-16; 8:45 am]
BILLING CODE 4140-01-P
